ProfileGDS5678 / 1433118_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 27% 27% 25% 26% 27% 27% 37% 26% 28% 27% 27% 27% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6701128
GSM967853U87-EV human glioblastoma xenograft - Control 22.6224627
GSM967854U87-EV human glioblastoma xenograft - Control 32.618527
GSM967855U87-EV human glioblastoma xenograft - Control 42.527425
GSM967856U87-EV human glioblastoma xenograft - Control 52.550326
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6954127
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6563927
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8436537
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5830726
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6358328
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6138827
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5862227
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6186427
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6666130